Baxter International (BAX) vs Insulet (PODD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Baxter International (BAX) has outperformed Insulet (PODD) over the past year, gaining 4.7% versus a loss of 57.1%. Over five years, PODD leads with a -55.3% price change compared with -69.9% for BAX. Baxter International is the larger company by market cap ($12.39 billion vs $9.32 billion), about 1.3 times the size, while Insulet is growing revenue faster (+30.7% vs +5.7%).
On valuation, Baxter International trades at a lower forward P/E (11.8x vs 17.4x for Insulet). Baxter International pays a dividend yielding 0.83%, while Insulet does not currently pay one. Insulet converts more of its revenue into profit, with a net margin of 9.1% versus -8.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BAX | PODD |
|---|---|---|
| Share price | $23.97 | $134.36 |
| Market cap | $12.39B | $9.32B |
| 1-day change | -1.60% | -0.27% |
| YTD return | +25.43% | -52.73% |
| 1-year return | +4.67% | -57.14% |
| 5-year return | -69.92% | -55.29% |
| P/E ratio (TTM) | — | 25.21 |
| Forward P/E | 11.75 | 17.38 |
| EPS (TTM) | $-1.88 | $5.33 |
| Dividend yield | 0.83% | 0.00% |
| Annual dividend | $0.20 | $0.00 |
| Revenue (latest FY) | $11.24B | $2.71B |
| Revenue growth (YoY) | +5.72% | +30.73% |
| Net income (latest FY) | $-957.00M | $247.10M |
| Gross margin | 30.05% | 71.63% |
| Operating margin | -2.74% | 17.50% |
| Net margin | -8.51% | 9.12% |
| 52-week high | $30.00 | $354.88 |
| 52-week low | $15.73 | $126.40 |
| Distance from 52-week high | -20.10% | -62.14% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +16.48% | +27.24% |
| Average volume | 6.63M | 1.69M |
| Shares outstanding | 517.00M | 69.35M |
| Employees | 37,500 | 5,400 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BAX has outperformed PODD by 61.8 percentage points over the past year.
- Insulet is more profitable, keeping 9.1 cents of every revenue dollar as net income versus -8.5 cents for Baxter International.
- Insulet grew revenue faster in its latest fiscal year (+30.73% vs +5.72%).
About Baxter International
BAX stock →Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
Health Care · Medical/Dental Instruments · 37,500 employees
About Insulet
PODD stock →Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Health Care · Medical/Dental Instruments · 5,400 employees
BAX vs PODD FAQ
Which is bigger, Baxter International or Insulet?
Baxter International (BAX) is larger, with a market capitalization of $12.39B compared with $9.32B for Insulet (PODD).
Which stock has performed better over the past year, BAX or PODD?
BAX returned +4.67% over the past 12 months, compared with -57.14% for PODD (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Baxter International or Insulet?
Baxter International pays a dividend yielding 0.83%, while Insulet does not currently pay a regular dividend.
Are Baxter International and Insulet in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.